An increase in intermediate CD14+ CD16+ monocytes in patients with different clinical severity of COVID-19 in comparison with healthy individuals has been observed before [42,43], but the exact mechanism of this phenomenon has not been elucidated yet. The gene discussed is FCGR3A; the disease is COVID-19.